Value-Based Pricing
Innovation Moves Down NICE’s Value Agenda
NICE’s future value-based drug pricing decisions won’t hinge on innovation, but will instead prioritize drugs that can demonstrate a wider societal benefit, or clearly address an unmet need, writes Julian Upton ...Read more
Regulatory
Social Media Raises Concerns for Marketers, Trial Sponsors
A recent report from the Tufts Center for the Study of Drug Development finds that sponsors are treading lightly in the use of websites, chat rooms and interactive online communications to support clinical research programs, focusing primarily on patient recruitment
...Read more
Reducing Trial Risk and Cost: Integrated Trial Management, Performance Analytics and Mobility in the Cloud
View the webcast to find out how leading sponsors are gaining actionable insight into clinical trials to accelerate fast, informed decision-making that accelerates clinical development while reducing trial cost and risk. Oracle Health Sciences experts discuss how to increase efficiency and productivity through comprehensive performance analytics and mobility.  Read more
Oncology
Casing Cancer: ASCO Launches New Cancer Care Series
A new ASCO report on the state of cancer care in the US goes beyond incidence reports and mortality data to consider drug prices, pressures faced by oncologists in their practices, and other factors intrinsic to delivery of care and ultimately health outcomes ...Read more
Deals
M&As and IPOs Shake Up CMO Industry
The CMO industry is undergoing a wave of ownership changes, including acquisitions, divestitures, and IPOs. Ownership changes can lead to significant changes in a company’s strategy, focus, and prospects, so it is important for bio/pharmaceutical companies to review the implications of a key supplier’s change in ownership ...Read more
ZS Associates – Genuine Customer Centricity in Sales and Marketing:
You need to embrace all marketing channels, and see which ones work for each customer—instead of playing a single instrument, you need to  conduct an orchestra.
Global
Read the Pharm Exec Global Digest Compliance & Transparency Special
In this month’s new issue: Devising and implementing a robust anti-corruption program; Confessions of a compliance officer; Compliance and reporting: the case for a single system; and more ...Read more
Leadership
Pharm Exec’s Emerging Pharma Leaders 2014 — Nominate Now
It's time for you to tell us who you think should receive Pharm Exec's 2014 Emerging Pharma Leadership Award. Read more for details of how to nominate a colleague — or yourself. ...Read more
White Paper – Global Digital Security:
For health care companies, the question is not whether your organization will suffer a data breach, but when? And, how serious will the consequences be of such a breach? Because health information is both so valuable and so sensitive, the health care sector is particularly susceptible to public disclosure of data breaches. inVentiv Health Digital+Innovation outlines recommendations for developing a comprehensive strategy to prevent, prepare and respond to attacks. Read more
Special Feature
Pharm Exec’s Annual Press Audit 2014
Pharm Exec's latest survey of press issues shows that media coverage continues to remain on balance negative toward the industry, by a slight margin: 47% this year compared to a 46% average over the last seven years ...Read more |
|
|
 //Cipher Pharmaceuticals Inc. (Mississauga, ON) announced that Larry Andrews will step down as President and Chief Executive Officer. He will remain with the Company while the Board searches for a replacement.//Recro Pharma, Inc. (Malvern, PA) announced the appointments of Alfred F. Altomari and Dr. Michael Berelowitz to the its Board of Directors.//Amgen (Thousand Oaks, CA) named David Piacquad as Senior Vice President.//Tetraphase Pharmaceuticals, Inc. (Watertown, MA) added Nancy J. Wysenski to its Board of Directors.// |
|
